Two Bear Capital

Kannan Kothandaraman shared some of his insights with me about the challenges of network operations and management and where his company Selector is headed, as it raises new $$ for the road ahead. “Some customers have like 30-40 different tools that they are using, each of them starts to complain whenever there is an issue,” Kothandaraman told me. “The number one criteria that we are judged on is noise reduction.”

Congratulations to Selector and its founders Kannan Kothandaraman and Nitin Kumar!?The Two Bear Capital portfolio company announced the close of its $33M Series B funding round today. The round was led by Ansa Capital who was joined by Two Bear and existing investors Atlantic Bridge, SineWave Ventures, AT&T Ventures, Bell Ventures, Singtel Innov8 and Hyperlink Ventures. The funding will accelerate the development and adoption of Selector's novel AIOps solution. The company’s technology is already deployed by some of the largest telecommunications and enterprise companies and is seeing increased adoption by new large-scale customers. You can read the news here: https://lnkd.in/ein9RyDF ? #AI #SelectorAI #SeriesB #MachineLearning

Our team at Two Bear Capital continues to grow. Please join us in welcoming Eric Fulton as a Venture Partner. Eric will be working to identify new opportunities and will support our existing founders and portfolio companies who operate in enterprise technology, cybersecurity, and healthcare IT. Eric joins us from Citadel Securities where he was responsible for global telecommunications. We feel so lucky to have Eric on the team. Read Eric's bio here: https://lnkd.in/epX3FgyB Connect with Eric on LinkedIn here: Eric F. #TwoBearCapital #VentureCapital?

?? You'll find more of our "Why Switch to Rocky" mini series on YouTube! Go to CIQ's YouTube channel here: https://hubs.li/Q02YyZ3J0 #CIQ #EnterpriseLinux #RockyLinuxSponsor #RLC

A big thank you to Wilson Sonsini Goodrich & Rosati for inviting me to be part of the Investor Panel at their inaugural Biotech Summit! It was an honor to represent Two Bear Capital by sharing insights alongside such an impressive group of industry leaders and innovators including Olga Danilchanka from MRL Ventures Fund LLC, Jessica Alston from F-Prime Capital, and Ray Camahort Ph.D. from Novo Holdings. I’m also truly appreciative of the opportunity to be featured in the event’s video — it was a fantastic experience to contribute to the conversation on the future of biotech investment and innovation. Thank you to Jennifer Fang, Kassandra Castillo and Farah Gerdes at Wilson Sonsini Goodrich & Rosati for inviting me to participate. Looking forward to continuing the dialogue and seeing the incredible work that’s being done in the biotech space! ?? #Biotech #Investment #Innovation #WilsonSonsini #BiotechSummit #Grateful #FutureOfBiotech

We are thrilled to announce major expansions at TileDB, including strategic appointments to our board and leadership team and the opening of our NYC office. New board appointments: ? George Llado - Former SVP & CIO of Alexion Pharmaceuticals, Inc., joining as Independent Director ? Jeff Miller - Operating Partner at Two Bear Capital, joining as Board Observer Senior Leadership appointments, collectively representing decades of experience in the database and SaaS markets: ? Eric Goldstein - Chief Revenue Officer ? Julie Bryce - Chief Marketing Officer ? Tom Hannon - Head of Finance ? Paolo Narvaez - VP of Product With these new appointments, we are expanding our leadership capabilities to enhance our market reach and strengthen our go-to-market capability, solidifying TileDB's status as the preferred foundation for scientific breakthroughs.

TileDB, the database designed for scientific discovery, announced today it is now utilized by 50% of the top 20 global pharmaceutical companies, including industry giant Boehringer Ingelheim.?This is an incredible achievement for this Two Bear Capital portfolio company. The multimodal data management company also announced it has strengthened its leadership with new board members and executive appointments. George Llado joined the board, Jeff Miller became a board observer, and senior executives like Eric Goldstein, Julie Bryce, Tom Hannon and Paolo Narvaez were announced. Congratulations to all. Read the news here: https://lnkd.in/exrqxN-3 ? #TileDB #TwoBearCapital #multimodal #multiomics?

"By implementing Arch’s AI-powered manufacturing solutions, a manufacturer achieved impressive results, with nearly $3M in combined annual savings: $600,000 from reduced component waste and $2,200,000 from downtime reduction." Read more about how a leading automotive electronics manufacturer reduced attrition and downtime for increased efficiency with Arch: https://lnkd.in/gu4Z_ZEu #casestudy #manufacturing #optimization

While targeted therapies have been a major advance in the treatment of cancer, most cancers are caused by loss of function (LOF) mutations and have no targeted therapies. Learn more about LOF mutations and how Leapfrog Bio is accelerating cancer drug development by identifying clinical-stage molecules that can be retargeted as directed therapies for cancers caused by LOF. #drugdiscovery #precisionmedicine #biotechnology

Two Bear Capital’s Mark Adams will be speaking at the AI Driven Drug Discovery Summit in Boston this Wednesday (November 13th). Mark will be on a panel entitled “Investment Trends in AI-Driven Drug Discovery.”?Lu Zhang with Fusion Fund, Mani Foroohar with Leerink Partners, and Aiden Aceves, Ph.D. with Insight Partners will join Mark in this session.?Together, they will explore the current landscape of AI investment in pharmaceutical R&D. The panel will look at opportunities and challenges for AI-startups in drug discovery to refine platform development strategies, and will cover what venture capitalists look for in AI-driven drug discovery companies. Mark will also be a judge in the Innovation Incubator session on Thursday, November 14th. In this session, six startups will take the stage and present to potential partners. Register here: https://lnkd.in/eruQupkp #AIDDD?#aidrivendrugdiscovery #aidrugdiscovery #twobearcapital